Home/Pipeline/PLD-107

PLD-107

ADC for AML & solid tumors

PreclinicalActive

Key Facts

Indication

ADC for AML & solid tumors

Phase

Preclinical

Status

Active

Company

About PeLeMed

AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases